174 related articles for article (PubMed ID: 15465798)
1. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure?
Nijveldt RJ; Siroen MP; Teerlink T; van Leeuwen PA
J Nutr; 2004 Oct; 134(10 Suppl):2848S-2852S; discussion 2853S. PubMed ID: 15465798
[TBL] [Abstract][Full Text] [Related]
2. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
3. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.
Nijveldt RJ; Teerlink T; van Leeuwen PA
Clin Nutr; 2003 Feb; 22(1):99-104. PubMed ID: 12553957
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
5. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.
Ferrigno A; Di Pasqua LG; Berardo C; Richelmi P; Vairetti M
World J Gastroenterol; 2015 May; 21(17):5131-7. PubMed ID: 25954086
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine and critical illness.
Brinkmann SJ; de Boer MC; Buijs N; van Leeuwen PA
Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):90-7. PubMed ID: 24281375
[TBL] [Abstract][Full Text] [Related]
8. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.
Nijveldt RJ; Teerlink T; Van Der Hoven B; Siroen MP; Kuik DJ; Rauwerda JA; van Leeuwen PA
Clin Nutr; 2003 Feb; 22(1):23-30. PubMed ID: 12553946
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Liu X; Xu X; Shang R; Chen Y
Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
[TBL] [Abstract][Full Text] [Related]
11. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
Baylis C
Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
[TBL] [Abstract][Full Text] [Related]
12. Increased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model.
Sheen JM; Chen YC; Tain YL; Huang LT
Int J Mol Sci; 2014 Mar; 15(3):3989-4006. PubMed ID: 24603538
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
Toutouzas K; Riga M; Stefanadi E; Stefanadis C
Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects.
Cable DG; Celotto AC; Evora PR; Schaff HV
Med Sci Monit; 2009 Sep; 15(9):BR248-53. PubMed ID: 19721392
[TBL] [Abstract][Full Text] [Related]
15. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA).
Nijveldt RJ; Teerlink T; Siroen MP; van Lambalgen AA; Rauwerda JA; van Leeuwen PA
Clin Nutr; 2003 Feb; 22(1):17-22. PubMed ID: 12553945
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
Böger RH
Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
[TBL] [Abstract][Full Text] [Related]
17. Imbalance of arginine and asymmetric dimethylarginine is associated with markers of circulatory failure, organ failure and mortality in shock patients.
Visser M; Vermeulen MA; Richir MC; Teerlink T; Houdijk AP; Kostense PJ; Wisselink W; de Mol BA; van Leeuwen PA; Oudemans-van Straaten HM
Br J Nutr; 2012 May; 107(10):1458-65. PubMed ID: 22129964
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine: clinical applications in pediatric medicine.
Tain YL; Huang LT
J Formos Med Assoc; 2011 Feb; 110(2):70-7. PubMed ID: 21377060
[TBL] [Abstract][Full Text] [Related]
19. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
[TBL] [Abstract][Full Text] [Related]
20. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure.
Mookerjee RP; Dalton RN; Davies NA; Hodges SJ; Turner C; Williams R; Jalan R
Liver Transpl; 2007 Mar; 13(3):400-5. PubMed ID: 17318866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
